Business Watch: Solstice, Element Cancel Deal; FDA Approves Daraxonrasib for Pancreatic Cancer
Chemical & Engineering News
"Solstice and Element have cancelled their deal," a recent report stated. The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for the treatment of pancreatic cancer, marking a significant development in the field.